Zydus & Zynesher Complete K-V Generics Acquisition for $60M

The acquisition covers K-V Pharma's certain packaging, manufacturing and laboratory facilities, as well as equipment specific to the generic business.

American drug company K-V Pharmaceutical announced yesterday that Zydus Pharmaceuticals USA Inc and its subsidiary Zynesher Pharmaceuticals USA LLC have completed the acquisition of assets of K-V Pharmaceutical's wholly owned generics subsidiary Nesher Pharmaceuticals for $60m.

The acquisition also covers K-V Pharma's certain packaging, manufacturing and laboratory facilities including some intellectual property rights, existing and future product opportunities, as well as equipment specific to the generic business.

K-V Pharma has also signed a supply deal with Zydus Pharma to offer third-party manufacturing services for Gynazole-1 and Clindesse.

Nesher CEO Greg Divis said that the company